Clinical Trial Update: A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) [Phase 3]

View source ↗

Summary

Phase 3 trial update on Intismeran Autogene (V940) in combination with pembrolizumab for high-risk melanoma (V940-001), with the study currently active but not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Intismeran Autogene (V940) (V940)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Melanoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING